Molecular Partners AG (MOLN:NASDAQ) closed at $3.56 on October 16, 2026, up 0.75% on the day. The stock trades 33.6% below its 52-week high of $5.36 and 1.1% above its 52-week low of $3.52. Over the past year, it lost 9.2%. Molecular Partners AG is part of the Health Care sector.
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| -6.07% | -15.44% | -11.00% | -19.27% | -9.18% |
In 252 trading sessions since October 16, 2025, MOLN closed higher on 103 days (41%). Its best day was November 6, 2025 (+16.24%) and its worst was March 13, 2026 (-10.40%). The stock moved 10% or more in a single session 6 times. It opened at least 5% above the previous day's high 6 times.
Molecular Partners AG is a clinical-stage biopharmaceutical company. The company focuses on the discovery, development and prospective commercialization of a new class of biopharmaceutical products. The firm develops protein therapeutics called DARPin therapeutics for the treatment of serious diseases, including cancer and sight-threatening disorders. The company's product pipeline is organized principally through three areas: Ophthalmology, including the creation of therapies for retinal diseases like wet age-related macular degeneration and diabetic macular edema; the Oncology pipeline comprises DARPin candidates with novel modes of action, including multi-DARPin compounds; and Immuno-oncology for anticancer treatment.
Find more stocks like MOLN with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.